Lipid formulation development: why softgels are the technology of choice: References

References

1. Mak KK. The role of DMPK science in improving pharmaceuticals. Drug Discov Today. 2022. doi:10.1016/j.drudis.2022.S1359644621004840.  

2. Roots Analysis. Oral Solid Dosage Manufacturing Market – Distribution by Type of Finished Dosage Form, Type of Packaging, Scale of Operation, Company Size, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035. Roots Analysis. Published March 30, 2023. Accessed September 2, 2025. 

3. Patheon. Five hidden risks in early-phase OSD formulation development. Patheon; June 10, 2025. Accessed August 25, 2025.  

4. Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475-486. doi:10.1038/nrd4609. 

5. Anitha C, Ramesh B. Formulation and evaluation of liquid filled hard gelatin capsule. Int J Creative Research Thoughts. 2023;11(10):169-176.

6. Müllertz A, Ogbonna A, Ren S, Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol. 2010;62(11):1622-1636. doi:10.1111/j.2042-7158.2010.01107.x. 

7. Piest M, Gupta S, Bernaerts A. Lipid based SMEDDS formulation of ibuprofen and phenylephrine for softgels. BioPharma Asia. January 16, 2017. Accessed September 5, 2025. 

8. van den Dries K, Teles H. Why are lipid formulations commonly used to enhance bioavailability? Webinar. Thermo Fisher Scientific (Patheon Pharma Services); [year unknown]. Accessed September 5, 2025.  

9. Stable liquid pharmaceutical formulations. WO2023219465A1. Published November 16, 2023.